Realbotix Faces a Pivotal Gamble: Nasdaq Listing Hinges on Supply Chain and Shareholder Approval

Realbotix is navigating one of the most volatile stretches in its short public history as it pursues a high-stakes reverse takeover of Onconetix (NASDAQ: ONCO). The goal: list its wholly owned subsidiary, Realbotix LLC, on the Nasdaq Capital Market. But the path is anything but smooth, with supply chain bottlenecks, a recent revenue decline, and a share price that swings wildly on every piece of news.

The stock closed the week at €0.21, down 6.14% on Friday, yet still up 25.88% over the past seven trading sessions. That bounce masks a year‑to‑date loss of roughly 24% and a 30‑day annualized volatility of 88.09% — an extreme reading that underscores how heavily the market is betting on the Nasdaq outcome. From the October 2025 high of €0.39, the share remains 44.42% below that peak.

The Funding Engine: A Debt‑Free Balance Sheet

One of the few clear positives is the company’s financial position. Realbotix has eliminated all debt and now carries a “super clean” balance sheet, according to management, with more than twelve months of operating capital. This liquidity provides a cushion while the reverse merger is completed, insulating the stock from short‑term financing risks.

The deal structure gives Realbotix significant upside: after the transaction, the parent company will retain a 75% to 90% stake in the Nasdaq‑listed entity. CEO Andrew Kiguel has framed the move as a value unlock, not a dilution event, arguing that the ONCO capital will provide non‑dilutive financing for growth. “After the Nasdaq listing there will be a clearer, more visible market value for the commercial robotics business — and better access to capital, institutional investors and long‑term growth opportunities,” he said.

Operational Reality: Thin Revenue, Delayed Deliveries

The near‑term business remains lean. In the second quarter of 2026 (Q2 2026), Realbotix reported revenue of only $225,000, down sharply from the prior year as it deliberately wound down its crypto operations to focus on humanoid robotics. Net income came in at $442,000, but that figure was driven by one‑time items rather than core operations. Management acknowledges that immediate revenue growth is limited and that the near‑term focus is on development.

A more structural challenge is the supply chain. Realbotix has been unable to secure enough Nvidia Thor processors, a critical component for its humanoid robots. The shortage is not a temporary hiccup; it is an ongoing constraint that threatens to delay commercial shipments just as the company tries to build momentum. On the production side, Realbotix has moved into a larger facility near Las Vegas to improve assembly capacity and streamline workflows, but without chips, higher volumes remain aspirational.

Should investors sell immediately? Or is it worth buying Realbotix?

Commercial Milestones and the Ambitious Target

Despite the headwinds, Realbotix has begun delivering real systems. In April it shipped initial units to telecom giant Ericsson, and in late June it entered the education sector with a U.S. school district deploying humanoid robots and AI assistants. These reference customers are important proof points, but they have not yet translated into meaningful recurring revenue.

The company’s long‑term target is ambitious: $100 million in quarterly revenue from AI and robotics within three to four years. For now, the entire business is valued at roughly $55 million — a fraction of the multi‑billion‑dollar valuations carried by some comparable robotics firms. That discount reflects the market’s skepticism about execution, not just size.

Chart Levels and Key Catalysts

Technically, the stock is testing important thresholds. The 200‑day moving average at €0.22 acts as resistance, currently just 4.67% above the closing price. Support sits at the 50‑day trendline, while the Relative Strength Index has cooled to 60, unwinding the overbought condition from earlier in the week. The 52‑week low of €0.15, set on June 29, 2026, remains a potential retest if the merger or supply chain falters.

The most immediate catalyst is the timeline for the Onconetix reverse takeover. The definitive agreement sets a deadline of October 31, 2026, for completion, but the deal still requires approval from both Onconetix shareholders and the TSX Venture Exchange. Any delay beyond that window would remove the Nasdaq premium that optimistic investors have already priced in.

Separately, the company is expected to provide an update on robot delivery timelines. As of early July 2026, neither the shareholder vote nor a clear resolution on the Nvidia chip shortage had been announced. Until those boxes are checked, Realbotix remains a high‑volatility bet on a single binary outcome.